Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller | -567,53 | 48,85k | Vente | 86,08 | 2,48k | -18,63% |
| 2026-05-27 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -23,15k | 2,00M | Vente | 86,42 | 133,29k | -14,80% |
| 2026-05-22 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -1,50k | 126,91k | Vente | 84,60 | 19,43k | -7,17% |
| 2026-05-18 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -620,00 | 5,25k | Derivative Exercise and Sale | 72,68 - 81,14 | 12,79k | - |
| 2026-05-15 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -17,97k | 1,47M | Vente | 81,82 - 82,07 | 156,44k | -10,30% |
| 2026-05-11 | Mr. Bernard J. ZovighianCEO & Director | -47,21k | 2,09M | Derivative Exercise and Sale | 79,96 | 114,94k | - |
| 2026-05-12 | Mr. Bernard J. ZovighianCEO & Director | -36,35k | 2,83M | Automatic Disposition | 77,92 - 78,40 | 114,94k | -24,03% |
| 2026-05-12 | Mr. Bernard J. ZovighianCEO & Director | -5,63k | 0,00 | Other Disposition | - | 114,94k | -4,67% |
| 2026-05-11 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -7,47k | 597,22k | Derivative Exercise and Sale | 79,96 | 174,40k | - |
| 2026-05-11 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | 5,99k | 0,00 | Derivative Exercise and Retained Stock | - | 174,40k | 3,56% |
| 2026-05-11 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -7,54k | 602,74k | Derivative Exercise and Sale | 79,96 | 20,93k | - |
| 2026-05-11 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | 6,05k | 0,00 | Derivative Exercise and Retained Stock | - | 20,93k | 40,63% |
| 2026-05-11 | Mr. Scott B. UllemInitié | -11,00k | 879,88k | Derivative Exercise and Sale | 79,96 | 294,62k | - |
| 2026-05-11 | Mr. Scott B. UllemInitié | 8,83k | 0,00 | Derivative Exercise and Retained Stock | - | 294,62k | 3,09% |
| 2026-05-07 | Mr. Wayne T. MarkowitzGM & Senior VP of Surgical Structural Heart | -490,00 | 40,67k | Sale to Issuer | 82,76 - 83,20 | 2,25k | -17,88% |
| 2026-05-11 | Mr. Wayne T. MarkowitzGM & Senior VP of Surgical Structural Heart | -593,00 | 47,28k | Vente | 79,73 | 2,25k | -20,85% |
| 2026-05-07 | Mr. Bernard J. ZovighianCEO & Director | -9,55k | 792,27k | Sale to Issuer | 82,76 - 83,20 | 130,28k | -6,83% |
| 2026-05-08 | Mr. Bernard J. ZovighianCEO & Director | -9,71k | 0,00 | Other Disposition | - | 130,28k | -6,94% |
| 2026-05-11 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -362,00 | 28,95k | Sale to Issuer | 79,96 | 12,79k | -2,75% |
| 2026-05-07 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -1,87k | 155,04k | Sale to Issuer | 82,76 - 83,20 | 166,81k | -1,11% |
| 2026-05-07 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -759,00 | 62,95k | Sale to Issuer | 82,76 - 83,20 | 13,15k | -5,46% |
| 2026-05-08 | Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller | -289,00 | 23,92k | Sale to Issuer | 82,76 | 3,05k | -8,67% |
| 2026-05-07 | Mr. Scott B. UllemInitié | -3,03k | 251,70k | Sale to Issuer | 82,76 - 83,20 | 283,43k | -1,06% |
| 2026-05-07 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -1,82k | 150,51k | Sale to Issuer | 82,76 - 83,20 | 13,26k | -12,04% |
| 2026-05-08 | Ms. Annette Maria BrulsCorp. VP of EMEA, Canada, & Latin America | -84,00 | 6,95k | Sale to Issuer | 82,76 | 3,38k | -2,43% |
| 2026-05-05 | Mr. Scott B. UllemInitié | 1,87k | 110,75k | Derivative Exercise and Retained Stock | 59,26 | 280,35k | 0,67% |
| 2026-05-05 | Mr. Scott B. UllemInitié | -11,13k | 263,28k | Derivative Exercise and Sale | 59,26 - 82,91 | 280,35k | - |
| 2026-05-03 | Mr. Scott B. UllemInitié | -620,00 | 52,07k | Sale to Issuer | 83,98 | 280,35k | -0,22% |
| 2026-05-03 | Mr. Bernard J. ZovighianCEO & Director | -515,00 | 43,25k | Sale to Issuer | 83,98 | 96,03k | -0,53% |
| 2026-05-05 | Mr. Bernard J. ZovighianCEO & Director | -523,00 | 0,00 | Other Disposition | - | 96,03k | -0,54% |
| 2026-05-01 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -2,04k | 49,40k | Derivative Exercise and Sale | 59,26 - 83,99 | 10,97k | - |
| 2026-05-03 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -252,00 | 21,16k | Sale to Issuer | 83,98 | 10,97k | -2,25% |
| 2026-05-03 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -469,00 | 39,39k | Sale to Issuer | 83,98 | 181,52k | -0,26% |
| 2026-05-03 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -282,00 | 23,68k | Sale to Issuer | 83,98 | 11,03k | -2,49% |
| 2026-04-09 | Mr. Scott B. UllemInitié | -13,00k | 270,21k | Derivative Exercise and Sale | 59,26 - 80,50 | 277,85k | - |
| 2026-04-06 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -1,02k | 22,14k | Derivative Exercise and Sale | 59,26 - 80,98 | 11,22k | - |
| 2026-04-02 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -22,68k | 474,11k | Derivative Exercise and Sale | 59,26 - 80,59 | 181,96k | - |
| 2026-03-11 | Mr. Scott B. UllemInitié | -13,00k | 333,56k | Derivative Exercise and Sale | 59,26 - 85,21 | 277,85k | - |
| 2026-03-11 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -1,02k | 26,62k | Derivative Exercise and Sale | 59,26 - 85,38 | 11,22k | - |
| 2026-03-02 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -11,34k | 302,46k | Derivative Exercise and Sale | 59,26 - 85,93 | 181,92k | - |
| 2026-02-25 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -24,00k | 2,01M | Vente | 83,84 | 164,37k | -12,74% |
| 2026-02-22 | Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller | -176,00 | 14,04k | Sale to Issuer | 79,78 | 2,40k | -6,82% |
| 2026-02-22 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -432,00 | 34,46k | Sale to Issuer | 79,78 | 11,22k | -3,71% |
| 2026-02-16 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -456,00 | 34,60k | Sale to Issuer | 75,87 | 11,65k | -3,77% |
| 2026-02-16 | Mr. Scott B. UllemInitié | -199,00 | 15,10k | Sale to Issuer | 75,87 | 277,85k | -0,07% |
| 2026-02-12 | Mr. Bernard J. ZovighianCEO & Director | -25,35k | 217,58k | Derivative Exercise and Sale | 59,26 - 77,13 | 96,15k | - |
| 2026-01-09 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -1,02k | 26,95k | Derivative Exercise and Sale | 59,26 - 85,70 | 12,15k | - |
| 2026-01-06 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -11,34k | 299,46k | Derivative Exercise and Sale | 59,26 - 85,98 | 188,28k | - |
| 2025-12-12 | Ms. Leslie Stone HeiszIndependent Director | -2,62k | 218,12k | Vente | 83,41 | 27,42k | -8,71% |
| 2025-12-12 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -11,39k | 953,75k | Vente | 83,74 - 83,79 | 188,28k | -5,70% |
| 2025-12-12 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -7,10k | 0,00 | Other Disposition | - | 188,28k | -3,63% |
| 2025-12-12 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -1,02k | 25,24k | Derivative Exercise and Sale | 59,26 - 84,03 | 12,11k | - |
| 2025-12-11 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -2,00k | 168,75k | Vente | 84,38 | 10,50k | -16,01% |
| 2025-12-08 | Mr. Bernard J. ZovighianCEO & Director | -25,35k | 328,85k | Derivative Exercise and Sale | 59,26 - 85,21 | 93,18k | - |
| 2025-12-10 | Mr. Bernard J. ZovighianCEO & Director | -3,86k | 322,37k | Automatic Disposition | 83,45 | 93,18k | -3,98% |
| 2025-12-10 | Mr. Donald E. BoboCorp. VP of Strategy & Corporate Development | -11,34k | 278,61k | Derivative Exercise and Sale | 59,26 - 83,83 | 206,77k | - |
| 2025-12-09 | Mr. Scott B. UllemInitié | -7,70k | 194,14k | Derivative Exercise and Sale | 59,26 - 84,47 | 277,56k | - |
| 2025-12-08 | Mr. Wayne T. MarkowitzGM & Senior VP of Surgical Structural Heart | -583,00 | 50,14k | Vente | 86,01 | 1,66k | -26,00% |
| 2025-11-10 | Mr. Scott B. UllemInitié | -13,00k | 309,76k | Derivative Exercise and Sale | 59,26 - 83,30 | 277,56k | - |
| 2025-11-10 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -1,02k | 23,75k | Derivative Exercise and Sale | 59,26 - 82,55 | 12,11k | - |
| 2025-09-13 | Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller | -262,00 | 20,32k | Sale to Issuer | 77,57 | 2,40k | -9,83% |
| 2025-09-14 | Mr. Wayne T. MarkowitzGM & Senior VP of Surgical Structural Heart | -650,00 | 50,42k | Sale to Issuer | 77,57 | 2,24k | -22,48% |
| 2025-08-25 | Mr. Daveen ChopraCorp. VP of Transcatheter Mitral & Tricuspid Therapies | -2,50k | 204,87k | Vente | 81,95 | 12,50k | -16,67% |
| 2025-08-18 | Mr. Larry L. WoodInitié | -8,95k | 168,33k | Derivative Exercise and Sale | 59,26 - 78,06 | 182,84k | - |
| 2025-07-28 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -4,11k | 326,90k | Vente | 79,46 | 12,11k | -25,36% |
| 2025-07-11 | Ms. Annette Maria BrulsCorp. VP of EMEA, Canada, & Latin America | -109,00 | 8,59k | Sale to Issuer | 78,80 | 3,43k | -3,08% |
| 2025-07-07 | Mr. Daniel J. LippisCorp. VP of JAPAC (Japan, Greater China & Asia Pacific) | -333,00 | 25,57k | Sale to Issuer | 76,79 | 16,22k | -2,01% |
| 2025-06-16 | Mr. Larry L. WoodInitié | -8,95k | 142,92k | Derivative Exercise and Sale | 59,26 - 75,23 | 182,84k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
